Actionable Insights into Your Mitral Regurgitation Patients

Soundos Moualla, MD, FACC, FSCAI
Interventional Cardiology
Dignity Health, Yavapai Regional Medical Center

The CardioCare platform allows us to look at referral patterns for our structural heart patients by pathology. Actionable insights from CardioCare powered an educational program for our primary care physicians, cardiologists, and hospitalists to reevaluate the change in guidelines-recommended therapy for mitral regurgitation (MR).

At Yavapai, we realized that we had a large number of medically managed AS & MR patients that met guideline-directed recommendations for procedural intervention. When we reviewed the data we identified variability in care patterns.

After implementing these targeted outreach & education practices discovered from CardioCare’s data, we were able to reduce our medical management rates by 10%, driving more appropriate procedural therapy options for these patient populations.

(1) Analysis represents patients identified between 10/31/2018 and 07/01/2021. Data was collected on 07/01/2021.

By reducing the medical management rate, we were able reduce variability in care for this patient population, leading to better outcomes overall and improved patient satisfaction. With CardioCare, we have continued to achieve our goals and challenge our program to grow better for our patients and community. 

Watch my presentation below to learn more. 

#DigitalHealth #PrecisionMedicine #ArtificialIntelligenceSolutions

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital